Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Abstract Background Time proxies based on blood biomarkers may facilitate understanding of the timing of biomarker change and symptom onset in Alzheimer's disease (AD) and could potentially enable biological staging of AD. Compared to CSF biomarkers or brain imaging, blood biomarkers are more accessible and less burdensome, making a “plasma clock” a practical and useful tool. Method Longitudinal plasma %p‐tau217 ( p ‐tau217 concentration divided by np‐tau217 concentration x 100) measurements from individuals enrolled in the Knight ADRC ( n = 420) or ADNI ( n = 392) cohorts were analyzed to develop plasma clocks for each cohort. The %p‐tau217 values were transformed into a time scale by integrating the inverse of the modeled rate of change. A %p‐tau217 value of 4.06%, which corresponds to amyloid PET Centiloid=20, was considered the threshold for positivity and set as time zero. The estimated age at %p‐tau217 positivity was then used to predict symptom onset, defined as a change in Clinical Dementia Rating® (CDR) from CDR=0 to CDR>0. Result The rate of change for plasma %p‐tau217 was relatively consistent between 0.65‐8.16% (Figure 1) and was used to construct independent plasma %p‐tau217 clocks for the Knight ADRC and ADNI cohorts (Figure 2). For individuals with plasma %p‐tau217 measured before and after positivity (4.06%), the estimated age at positivity based on the clock was strongly correlated with the actual age at conversion (Knight ADRC: R2=0.646, r=0.807; ADNI: R2=0.790, r=0.891). The Knight ADRC and ADNI plasma clocks provided highly similar estimates of the age at %p‐tau217 positivity for individuals in either study (adjusted R 2 =0.993, Pearson r=0.997, Figure 2). The estimated age at plasma %p‐tau217 positivity predicted the age at symptom onset (Figure 3) in the Knight ADRC (Spearman r=0.421, adjusted R 2 =0.151) and ADNI cohorts (Spearman r=0.648, adjusted R 2 =0.397). Conclusion Two independently constructed %p‐tau217 plasma clocks had strong correlations with actual time measures and were consistent across the two cohorts. Additionally, the age at %p‐tau217 positivity predicted symptom onset. Overall, these findings suggest that plasma %p‐tau217 may be useful in predicting symptom onset and in biological staging of AD.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 420 participants. Using repeated blood measurements of the tau marker %p-tau217, researchers built a 'plasma clock' that estimates when a person first becomes biomarker-positive and may help predict when Alzheimer's symptoms begin. Reported effect size: 4.06%; 8.16%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Petersen, K. K., Milà‐Alomà, M., Tosun, D., Li, Y., Saef, B. A., Shaw, L. M., et al. (2025). Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_099674

Vancouver

Petersen KK, Milà‐Alomà M, Tosun D, Li Y, Saef BA, Shaw LM, et al. Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_099674. PMID: 41442191.

BibTeX

@article{petersen2025-41442191,
  author  = {Petersen, Kellen K. and Milà‐Alomà, Marta and Tosun, Duygu and Li, Yan and Saef, Benjamin A. and Shaw, Leslie M. and Dage, Jeffrey L. and Zetterberg, Henrik and others},
  title   = {{Predicting onset of Alzheimer disease symptoms with a plasma \%p‐tau217 clock}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_099674},
  pmid    = {41442191},
  url     = {https://doi.org/10.1002/alz70856_099674}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Using repeated blood measurements of the tau marker %p-tau217, researchers built a 'plasma clock' that estimates when a person first becomes biomarker-positive and may help predict when Alzheimer's symptoms begin. The authors suggest this approach may be useful for predicting symptom onset and for staging the disease biologically.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 420 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Suzanne Elizabeth Schindler: h-index 56 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 12 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41442191)
Free to read 2 / 2 Free to read
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →